Search
Lexeo Therapeutics' CEO R. Nolan Townsend discusses a recent acquisition in Friedreich's ataxia and upcoming data in PKP2 arrhythmogenic cardiomyopathy
He describes how the company has transformed from being a gene therapy company focused on cardiology to having a broader approach to treating the root of disease.
6 hours ago
Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on PKP2 ACM, and more
He describes the clinical data in FA cardiomyopathy that was announced this month, and explains how the company is preparing to begin a clinical trial for accelerated approval by early 2026. Plus, how we should expect more ACM data in 2025.
Apr 23, 2025
Lexeo Therapeutics' CEO on using gene therapy for cardiovascular and Alzheimer's disease
Noland Townsend describes the science behind Lexeo's lead programs.
Feb 2, 2024
.png){kind=logo}